Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Abroad (travel likely)RecruitingPHASE1

Conditions

Refractory Malignant Solid Tumors · mRNA Vaccine · Interleukin

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Department of Radiation Oncology, Chengdu, Sichuan, China
Contact: Study coordinator (Xingchen Peng, Professor)
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Xingchen Peng, PhD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Refractory Malignant Solid Tumors · mRNA Vaccine · Interleukin

Abroad (travel likely)RecruitingPHASE1

Chengdu, China

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Malignant Solid Tumors · Other Neoplasms Solid Tumors · Pediatric Solid Tumor

Abroad (travel likely)Recruiting

Bethesda, United States · Portland, United States

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Refractory Solid Tumor · Hepatocellular Carcinoma · Malignant Solid Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

Germantown, United States · Memphis, United States

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Wilms Tumor · Rhabdoid Tumor · Malignant Peripheral Nerve Sheath Tumors

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Palo Alto, United States